Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch & Lomb CorpBLCO · Entity 3756 | EVP and CFO | August 05, 2026 | August 07, 2026 |
| Bausch Health Companies Inc.BHC · Entity 4363 | EVP & Chief Financial Officer | March 03, 2022 | March 07, 2022 |
| TE Connectivity plcTEL · Entity 3004 | Director | November 13, 2025 | November 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch & Lomb Corp
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 393,527 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Grant · Acquired 50,335 · Balance 393,527 F1: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common shares, no par value, of Bausch + Lomb Corporation underlying an award of performance stock units ("PSUs") originally granted to the reporting person on February 28, 2024 under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated, that satisfied the applicable performance conditions at the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, subject generally to the reporting person's continued employment through such date.
Bausch Health Companies Inc.
Report date March 03, 2022 · Filed March 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 119,455 |
Reported balance
After 2022-03-03 transaction · row 1
1 source rowRow 1 · 2022-03-03 · Tax withholding · Disposed 1,242 · Balance 119,455 F1: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. |
Filing footnotes · ownership attribution and instrument terms
F1: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
TE Connectivity plc
Report date November 13, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,206 |
Ending reported balance
After 2025-11-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-11-13 · Grant · Acquired 838 · Balance 1,609 F1: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan. Row 2 · 2025-11-13 · Tax withholding · Disposed 403 · Balance 1,206 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of shares by the Issuer under directors' compensation program and Issuer's stock and incentive plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2020 Filed Feb 22, 2020 02:56 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 8,943 | $26.46 | $236,631.78 |
DisclosureSEC source: 0001127602-20-007078 · form4.xml · nonDerivative · entry 3 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,917 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:56 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 4,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007078 · form4.xml · derivative · entry 4 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,096 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F2 · derivative.expiration_date: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on March 3, 2017 with the maximum potential award amount of 8,534 PSUs. Any portion of the award not vested on February 19, 2020 were cancelled as of that date. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:56 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 22,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-007078 · form4.xml · nonDerivative · entry 2 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,860 Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 02:56 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Stock, No Par Value | 4,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-007078 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. F2 · shares: On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. F3 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 21:21 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 1,694 | $29.42 | $49,837.48 |
DisclosureSEC source: 0001127602-20-001369 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,750 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:14 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 6,370 | $20.73 | $132,050.10 |
DisclosureSEC source: 0001127602-19-021018 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,444 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 20:27 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 1,217 | $23.56 | $28,672.52 |
DisclosureSEC source: 0001127602-19-011032 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,814 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:04 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 22,149 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001127602-19-009240 · form4.xml · derivative · entry 2 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,149 Underlying: Common Shares, No Par Value · 22,149 shares Expires 2029-02-27 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:04 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 7,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009240 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,031 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 1,696 | $21.25 | $36,040.00 |
DisclosureSEC source: 0001127602-19-001763 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,421 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 21:15 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 6,142 | $22.08 | $135,615.36 |
DisclosureSEC source: 0001127602-18-020184 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,117 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:58 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantRestricted Share Units · Derivative | 7,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011039 · form4.xml · derivative · entry 3 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,104 Underlying: Common Stock · 7,104 shares Expires 2021-03-07 F3 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 3,552 and the maximum number that can be distributed is 7,104. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. F3 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 3,552 and the maximum number that can be distributed is 7,104. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:58 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 31,697 | $0.00 Strike: $15.32 | $0.00 |
DisclosureSEC source: 0001127602-18-011039 · form4.xml · derivative · entry 2 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,697 Underlying: Common Shares, No Par Value · 31,697 shares Expires 2028-03-07 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:58 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 10,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011039 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,259 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 20:30 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 1,826 | $23.85 | $43,550.10 |
DisclosureSEC source: 0001127602-18-001439 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,605 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 20:45 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 6,159 | $12.51 | $77,049.09 |
DisclosureSEC source: 0001127602-17-021083 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,431 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:27 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantNon-Qualified Stock Options (right to purchase) · Derivative | 31,430 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001681871-17-000010 · primary_doc.xml · derivative · entry 3 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,430 Underlying: Common Shares, no par value · 31,430 shares Expires 2027-03-01 F3 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| January 06, 2017 Filed Mar 3, 2017 23:27 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantRestricted Share Units · Derivative | 8,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001681871-17-000010 · primary_doc.xml · derivative · entry 2 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,534 Underlying: Common Stock · 8,534 shares Expires 2020-01-06 F2 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 4,267 and the maximum number that can be distributed is 8,534. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's total shareholder return (TSR) as measured on January 6, 2020 (the Measurement Date). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. F2 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 4,267 and the maximum number that can be distributed is 8,534. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's total shareholder return (TSR) as measured on January 6, 2020 (the Measurement Date). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. Read SEC document |
| January 06, 2017 Filed Mar 3, 2017 23:27 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 12,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001681871-17-000010 · primary_doc.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,590 F1 · shares: Represents the award of restricted share units (RSUs) which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.